Novartis and MMV initiate Phase IIb trial of KAF156 for malaria in Africa

Novartis and Medicines for Malaria Venture (MMV) have initiated a Phase IIb clinical trial of KAF156 to treat multidrug-resistant malaria in Africa.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news